Japanese traditional herbal medicine reduces use of pregabalin and opioids for pain in patients with lumbar spinal canal stenosis: a retrospective cohort study

Mitsuhiko Oohata, Yuko Aoki, Michiko Miyata, Hiroki Mizobe and Kenji S. Suzuki*

Abstract
Background: There has been an increase in the number of Japanese patients with lumbar spinal canal stenosis (LSCS) who complain of chronic pain or motor disturbance in the lower back or extremities. These patients are often treated with anti-convulsive drugs, opioids, antidepressants, acetaminophen, or nonsteroidal anti-inflammatory drugs, all of which can cause side effects. For this reason, Japanese traditional herbal medicine (Kampo) is of interest, because it produces fewer adverse reactions. The aim of this retrospective cohort study was to analyze the effects of Kampo in patients with LSCS.

Findings: A total of 151 patients with LSCS were divided into two groups based on treatment with (n = 111, group K) and without (n = 40, group N) Kampo. Use of pregabalin and opioids decreased significantly in group K (p < 0.001). The hazard ratio for opioid discontinuation was 0.220 (p = 0.004) for group N vs. group K, while that for pregabalin and antidepressants discontinuation were 0.589 (p = 0.202) and 0.509 (p = 0.377), respectively. The mean duration of hospital visits and treatment did not differ between the groups, but the number of dropouts was significantly higher in group N (p < 0.0001). The hazard ratio for patient dropout was 4.118 (p = 0.001) for group N vs. group K.

Conclusions: Kampo led to discontinuation of opioid use for pain in patients with LSCS, and patients who were treated with Kampo were more likely to continue treatment.

Keywords: Japanese traditional herbal medicine, Lumbar spinal canal stenosis, Pain management, Kampo, Oriental medicine
The aims of this study were to analyze the recent use of Kampo in our outpatient pain clinic and to evaluate the effects of Kampo on outcomes with respect to its usability for pain management in outpatients. In addition, according to the hypothesis that a combination therapy using Kampo alongside Western medicine may have value, we examined the treatment progress of LSCS patients who complained of chronic low back pain, the most common condition in the outpatient department of our pain clinic in a retrospective cohort.

Patients and methods
The study was approved by the ethics committee of Iwate Medical University Graduate School of Medicine (No H29-56). Clinical data for patients with LSCS admitted for ambulatory care between January 2015 and December 2016 were obtained from electronic records. LSCS patients who continued to visit our hospital for over 1 month were included in this study. To exclude acute nociceptive pain, we excluded subjects whose treatment ended within 1 month. The diagnosis of LSCS was made on the basis of clinical symptoms, e.g., low back pain, numbness in a lower extremity, or intermittent claudication seen in magnetic resonance imaging (MRI) of the lumbar spine. Observation and diagnosis using MRI were performed by radiologists in our institution. Patients with LSCS who received treatment for other painful diseases were excluded. A total of 151 patients were enrolled and divided into two groups; patients in group K were prescribed Kampo (n = 111), while those in group N were not (n = 40). Data were collected on the following patient characteristics: therapeutic regimens involving nerve block or near-infrared light therapy, rehabilitation, and drug prescriptions. We also assessed periods of hospital attendance, and outcomes that involved either an end to therapy, continuation of therapy, or dropout during the observation period. These data were compared between the two groups.

SPSS version 22 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The Shapiro-Wilk test was used to determine whether data were normally distributed. Continuous data were expressed as median, 25th and 75th percentiles, or as mean ± standard deviation. Categorical variables were expressed as numbers or as percentages of patients. Continuous variables were compared using a Mann-Whitney U test or an unpaired Student’s t test. Categorical data were assessed using a Chi-square test. In addition, we performed an event history analysis to evaluate the influence of several variables on event risks. The event risks during the observation period for each group were analyzed using a Cox proportional hazard model, in which the independent variables were taken from the results of a Chi-square test with significance level $p < 0.1$. A $p$ value < 0.05 was considered to be significant.

Results
The characteristics of the 151 patients in the study are shown in Table 1. About 60% of the patients were referrals from the Department of Orthopedics in our hospital, while fewer than 10% of patients had no letter of introduction. The formulas for Kampo prescriptions are shown in Table 2. Gosha-jinki-gan and Hachimi-jo-gan were prescribed for many patients. Side effects due to Kampo occurred in seven patients: abdominal pain with Gosha-jinki-gan and Keishi-ka-jyutubu-to, diarrhea with Shakuyaku-kanzo-to and Bushi-matsu, excessive sweating and chest pain with Keishi-ka-jyutubu-to, and pseudoaldosteronism with Shakuyaku-kanzo-to.

The details of the effects of Kampo on the reduction of use of other drugs are shown in Table 3. The number of patients who discontinued use of pregabalin was significantly larger in group K than in group N ($p = 0.0012$). Similarly,

| Table 1 | Demographic profile and source of referral of the patients |
|---------|------------------------------------------------------------|
| Item    | Group K (n = 111) | Group N (n = 40) | p value |
| Age (years) | 73.3 ± 9.4 | 70.8 ± 9.5 | 0.16 |
| Male/female | 60/51 | 21/19 | 0.87 |
| Height (cm) | 158.4 ± 10.4 | 158.4 ± 8.8 | 0.95 |
| Weight (kg) | 58.0 ± 11.7 | 62.3 ± 11.6 | 0.06 |
| Source | | | |
| Our hospital | 68 | 58 | |
| Orthopedics (%) | | | |
| Neurosurgery (%) | 3 | 12 | |
| Neurology (%) | 3 | 2 | |
| Others (%) | 1 | 0 | |
| Another institution | | | |
| Pain clinic (%) | 5 | 10 | |
| Others (%) | 10 | 8 | |
| No introduction (%) | 9 | 8 | |

Values are mean ± SD or number of patients

Table 2 | Details of prescribed Kampo medicines |
|--------|-------------------------------------|
| Name of drugs | Number of patients |
| Gosha-jinki-gan | 51 |
| Hachimi-jo-gan | 50 |
| Shakuyaku-kanzo-to | 31 |
| Keishi-ka-jujutsu-to | 26 |
| Bushi-matsu | 24 |
| Sokei-kaketsu-to | 15 |
| Tokishigaku-ka-goshui-shokyo-to | 12 |
| Yokukan-san | 10 |
| Gorei-san | 10 |
| Others | 65 |
the use of opioids discontinued more often in group K ($p = 0.0002$). On the other hand, the use of antidepressants slightly decreased in group K ($p = 0.063$). The estimated hazard ratio for discontinuation of opioids was $0.220$ (95% CI 0.078–0.615, $p = 0.004$) for group N vs. group K, while that for pregabalin and antidepressants were 0.589 (95% CI 0.261–1.328, $p = 0.202$), 0.509 (95% CI 0.114–2.227, $p = 0.377$), respectively. The number of patients who discontinued use of NSAIDs and/or acetaminophen was not different between the groups ($p = 0.891$).

The duration of hospital visits and treatment and the outcomes are shown in Table 4. The number of patients who dropped out, defined as not revisiting the hospital for more than 6 months during treatment, was significantly higher in group N ($p < 0.0001$). We did not ignore these dropout patients in all of the analysis. The hazard ratio for patient dropout was $4.118$ (95% CI 1.792–9.460, $p = 0.001$) for group N vs. group K.

**Discussion**

Japanese traditional herbal medicine (Kampo) is covered by national medical insurance and widely used for pain management [7, 8]. Kampo is thought to be beneficial in terms of a lower incidence of side effects compared to Western medicine. However, substantial knowledge and experience are required to use Kampo effectively because the theory of Oriental traditional medicine is complicated and difficult to understand. In addition, education in Oriental medicine has been limited in Japan, and currently, there is an insufficient number of practitioners. Furthermore, the preparations include multiple herbal medicines, which makes it difficult to obtain pharmacological evidence of therapeutic effects. This difficulty is increased because Kampo is administered based on the pattern of a patient’s condition, rather than on a diagnosis, and the periods required for efficacy differ based on the kinds of formulations [9–12].

In this study, we assessed the effects of Kampo on the clinical course of patients with LSCS who complained of low back pain. The incidence of side effects caused by Kampo formulas was only 6.3% (7/111 patients), while 62.5% of patients treated without Kampo had side effects such as constipation, nausea, sleepiness, eruption, or edema. Therefore, the combined administration of Kampo decreased side effects compared to the use of Western-style medicines alone. The Cox proportional hazards model analysis showed that the estimated hazard ratio for discontinuing opioids was $0.220$ (95% CI 0.078–0.615, $p = 0.004$) for group N vs. group K, while that for pregabalin and antidepressants were 0.589 (95% CI 0.261–1.328, $p = 0.202$) and 0.509 (95% CI 0.114–2.227, $p = 0.377$), respectively. This means that the treatment with Kampo decreased side effects compared to the use of Western-style medicines alone.

**Table 3** The number of patients who were prescribed each drug and were followed-up

| Group     | Prescription | Decrease | Discont |
|-----------|--------------|----------|---------|
| Group K   | 69/111 (62.2%) | 45/69*** (65.2%) | 36/69*** (52.9%) |
| (n = 115) |              |          |         |
| Group N   | 19/40 (47.5%) | 2/19 (10.5%) | 2/19 (10.5%) |
| (n = 44)  |              |          |         |

| Drug                  | Group K | Group N | $p$ value |
|-----------------------|---------|---------|-----------|
| Pregabalin            | 69/111  | 19/40   | 0.172     |
| Opioid                | 74/111  | 28/40   | 0.001     |
| Antidepressant        | 22/111  | 2/6     | 0.063     |
| NSAIDs/acetaminophen  | 54/111  | 2/6     | 0.001     |

*Decrease decrease in the dose of drug prescribed, Discont discontinuation of the drug prescribed

*p < 0.1; **p < 0.05; ***p < 0.01 vs. group N

**Table 4** Duration of hospital visits and outcomes

| Outcome                  | Group K (n = 111) | Group N (n = 40) | $p$ value |
|--------------------------|-------------------|------------------|-----------|
| Ended treatment          | 49.5%             | 35.0%            | 0.113     |
| Visiting period (months) | 12.0 (4.5, 24.5)  | 5.0 (3.3, 16.3)  | 0.172     |
| Continued treatment      | 42.3%             | 27.5%            | 0.098     |
| Visiting period (months) | 35.0 (20.5, 54.0) | 41.0 (19.0, 69.5)| 0.592     |
| Dropped out              | 8.1%              | 37.5%            | <         |
| Visiting period (months) | 8.0 (4.0, 26.0)   | 34.0 (16.5, 50.5)| < 0.0001  |

Values are percentages of patients (%) and median (interquartile range)

*p < 0.05 vs. group N
prospective trial of Kampo, to validate the findings in this study.

Abbreviations
LSCS: Lumbar spinal canal stenosis

Funding
There was no funding obtained for this study.

Authors’ contributions
KSS designed the study. MO mainly wrote the manuscript with analysis and interpretation of the data. All authors contributed to the management of patients and contributed to the writing and revision of the manuscript for submission. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the ethics committee of Iwate Medical University Graduate School of Medicine (approval number; H29-56).

Competing interests
The authors declare that they have no competing interest.

Received: 26 July 2017 Accepted: 23 October 2017
Published online: 27 October 2017

References
1. Takura T, Miki K. The future of medical reimbursement for orthopedic surgery in Japan from viewpoint of the health economy. J Orthop Sci. 2016;21:273–81.
2. Hill JC, Whitehurst DGT, Lewis M, Bryan S, Dunn KM, Foster NE, Konstantinou K, Main CJ, Mason E, Somerville S, Sowden G, Vohora K, Hay EM. Comparison of stratified primary care management for low back pain with current best practice (star back): a randomized controlled trial. Lancet. 2011;378:1560–71.
3. Kalichman L, Hunter DJ. Diagnosis and conservative management of degenerative lumbar spondylolisthesis. Eur Spine J. 2008;17:327–35.
4. Tran QH, Duong S, Finlayson RJ. Lumbar spinal stenosis: a brief review of the nonsurgical management. Can J Anesth. 2010;57:694–703.
5. Arai YCF, Yasui H, Isai H, Kawai T, Nishihara M, Sato J, Ikemoto T, Inoue S, Ushida T. The review of innovative integration of Kampo medicine and Western medicine as personalized medicine at the first multidisciplinary pain center in Japan. EPMA J. 2014;5:10.
6. Takayama S, Iwasaki K. Systematic review of traditional Chinese medicine for geriatrics. Geniatr-Gerontol Int. 2017;17:679–88.
7. Hijioka Y. Analgesic treatment with Kampo prescription. Expert Rev Neurotherapeutics. 2006;6:795–802.
8. Hamauchi T, Yoshino T, Horiba Y, Watanabe K. Goshajinkignan for low back pain: an observational study. J Altern Complement Med. 2017;23:208–13.
9. Kawago K, Shindo S, Inoue H, Akasaka J, Motohashi S, Urabe G, Sato M, Uchiyama H, Ogino H. The effect of Hachimi-jo-gan (Ba-Wei-Di-Huang-Wan) on the quality of life in patients with peripheral arterial disease—a prospective study using Kampo medicine. Ann Vasc Dis. 2016;9:288–94.
10. Watanabe K, Kobayashi T, Tomii M, Sekiguchi Y, Uchida K, Aoki T, Cyong JC. Effects of Kampo herbal medicine on plasma melatonin concentration in patients. Am J Chin Med. 2002;30:65–71.
11. Katagiri F, Inoue S, Sato Y, Itoh H, Takeyama M. Comparison of the effects of Sho-hange-ka-bukuyuto and Nichin-to on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure. Biol Pharm Bull. 2004;27:1679–82.
12. Ushiroiyama T, Ikeda A, Sakuma K, Ueki M. Changes in serum tumor necrosis factor (TNF-alpha) with kami-shyoyo-san administration in depressed climacteric patients. Am J Chin Med. 2004;32:621–9.